These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34911567)

  • 61. Cannabis constituent synergy in a mouse neuropathic pain model.
    Casey SL; Atwal N; Vaughan CW
    Pain; 2017 Dec; 158(12):2452-2460. PubMed ID: 28885457
    [TBL] [Abstract][Full Text] [Related]  

  • 62. THC and CBD effects on alcohol use among alcohol and cannabis co-users.
    Karoly HC; Mueller RL; Andrade CC; Hutchison KE
    Psychol Addict Behav; 2021 Sep; 35(6):749-759. PubMed ID: 33764086
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a "tobacco substitute".
    Hädener M; Gelmi TJ; Martin-Fabritius M; Weinmann W; Pfäffli M
    Int J Legal Med; 2019 May; 133(3):821-832. PubMed ID: 30612324
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
    Newton M; Newton DW
    J Am Psychiatr Nurses Assoc; 2020; 26(5):447-457. PubMed ID: 32508204
    [No Abstract]   [Full Text] [Related]  

  • 65. Current state of evidence of cannabis utilization for treatment of autism spectrum disorders.
    Agarwal R; Burke SL; Maddux M
    BMC Psychiatry; 2019 Oct; 19(1):328. PubMed ID: 31664964
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study.
    Hausman-Kedem M; Menascu S; Kramer U
    Brain Dev; 2018 Aug; 40(7):544-551. PubMed ID: 29674131
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.
    Eichler M; Spinedi L; Unfer-Grauwiler S; Bodmer M; Surber C; Luedi M; Drewe J
    Planta Med; 2012 May; 78(7):686-91. PubMed ID: 22411724
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
    Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
    Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains.
    Bidwell LC; Mueller R; YorkWilliams SL; Hagerty S; Bryan AD; Hutchison KE
    Cannabis Cannabinoid Res; 2018; 3(1):35-44. PubMed ID: 29607409
    [No Abstract]   [Full Text] [Related]  

  • 70. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
    Szaflarski JP; Bebin EM
    Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.
    Colizzi M; Ruggeri M; Bhattacharyya S
    Front Psychol; 2020; 11():833. PubMed ID: 32528345
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Medical Cannabis in Children.
    Aran A; Cayam-Rand D
    Rambam Maimonides Med J; 2020 Jan; 11(1):. PubMed ID: 32017680
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cannabidiol modulation of antinociceptive tolerance to Δ
    Greene NZ; Wiley JL; Yu Z; Clowers BH; Craft RM
    Psychopharmacology (Berl); 2018 Nov; 235(11):3289-3302. PubMed ID: 30238130
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
    Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
    Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
    Fasinu PS; Phillips S; ElSohly MA; Walker LA
    Pharmacotherapy; 2016 Jul; 36(7):781-96. PubMed ID: 27285147
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review.
    Bartoli F; Riboldi I; Bachi B; Calabrese A; Moretti F; Crocamo C; Carrà G
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33810033
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.
    Malone DT; Jongejan D; Taylor DA
    Pharmacol Biochem Behav; 2009 Aug; 93(2):91-6. PubMed ID: 19393686
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap.
    Cleirec G; Desmier E; Lacatus C; Lesgourgues S; Braun A; Peloso C; Obadia C
    Front Psychiatry; 2022; 13():899221. PubMed ID: 35686188
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Effects of Cannabis Use on Cognitive Function in Healthy Aging: A Systematic Scoping Review.
    Pocuca N; Walter TJ; Minassian A; Young JW; Geyer MA; Perry W
    Arch Clin Neuropsychol; 2021 Jul; 36(5):673-685. PubMed ID: 33159510
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain.
    Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM
    J Pharmacol Exp Ther; 2020 Jun; 373(3):416-428. PubMed ID: 32179573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.